News Releases

2011

Dec.22.2011 Leukotriene Receptor Antagonist "Onon® Dry Syrup 10%" has received approval for the additional indication of allergic rhinitis(57.3KB)
Dec.13.2011 Ono Enters into Drug Discovery Collaboration with Receptos on GPCR Protein Crystal Structure Determination Technology(27.1KB)
Dec.08.2011 Launch of an Intravenous Antiemetic Selective Neurokinin-1(NK1)Receptor Antagonist,"PROEMEND® Intravenous infusion 150mg"(80.4KB)
Nov.30.2011 FDA Acceptance of New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.(56.5KB)
Nov.14.2011 Announcement of the results from a Phase 2 study of “ONO-5163/KAI-4169”:a calcium sensing receptor agonist(69.5KB)
Oct.20.2011 Revisions of Consolidated Financial Forecasts(72.3KB)
Oct.04.2011 Ono to Enter into License Agreements with Merck KGaA(89.0KB)
Sep.29.2011 Additional Indication Application Filed for a Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting“EMEND® Capsule”for Pediatric Patients Aged 12 and older(62.7KB)
Sep.29.2011 New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.(111KB)
Sep.26.2011 Approval received for an Intravenous Antiemetic Selective Neurokinin-1(NK1)Receptor Antagonist,“PROEMEND® Intravenous infusion 150mg”(24.6KB)
Sep.21.2011 Ono and Bristol-Myers Squibb Enter into Strategic Agreement for Anti-PD-1 Antibody,ONO-4538/BMS-936558,and ORENCIA®(abatacept),Rheumatoid Arthritis Agent(70.8KB)
Sep.16.2011 Glactiv® has received approval for the additional indication of combination use with insulin(84.6KB)
Sep.15.2011 Ono Enters License Agreement with KAI Phamaceuticals,Inc.for KAI 4169(25.3KB)
Sep.15.2011 Launch of RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg,Once per 4week Oral Osteoposis Treatment in Japan(92.6KB)
Sep.14.2011 Ono Enters into License Agreement with Servier for Ivabradine(22.7KB)
Sep.14.2011 Launch of Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan(19.1KB)
Aug.24.2011 Helsinn Announced to have Initiated Global Pivotal Phase III Clinical Program to Evaluate Anamorelin (ONO-7643/RC-1291) in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia (19.3KB)
Jul.19.2011 Launch of Rivastach® Patch,for the Treatment of Dementia of Alzheimer's Type (120KB)
Jul.01.2011 Approval for RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg, Once per 4weeks Oral Osteoposis treatment in Japan (49.6KB)
Jul.01.2011 Approval for Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan (11.0KB)
Jun.27.2011 Lead Compounds Were Successfully Identified in Ion Channel Drug Discovery Collaboration with Evotec (35.7KB)
Jun.01.2011 Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue (45.1KB)
May.20.2011 Approval for Additional Indication Application of Type-2 Diabetes Drug,Glactiv Tablets
-Combination Therapy with Alpha-glucosidase Inhibitors- (14.2KB)
May.11.2011 Announcement on Financial Results for FY2010
May.11.2011 Announcement on Introduct of Corporate Officer System,Changes of Members of the Board of Directors and Appointment of Corporate Officers (69.1KB)
Apr.22,2011 Approval Received for Rivastach® Patch, for the treatment of Alzheimer's disease (168KB)
Apr.06,2011 Announcement on Cancellation of the Company's Own Shares (96.7KB)
Apr.05,2011 Launch of Orally Disintegrating Tablet of Staybla Tablets 0.1mg, a Drug for Overactive Bladder (16.5KB)
Mar.29,2011 Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines (54.4KB)
Mar.25,2011 Announcement on Results and Completion of Acquisition of the Company’s Own Shares (99.7KB)
Jan.11,2011 Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease (15.3KB)